

Selim Cellek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4720521/publications.pdf>

Version: 2024-02-01

72
papers

3,926
citations

147566

31
h-index

118652

62
g-index

74
all docs

74
docs citations

74
times ranked

2881
citing authors

#	ARTICLE	IF	CITATIONS
1	Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: An insight into endotoxin shock. <i>Biochemical and Biophysical Research Communications</i> , 1990, 173, 541-547.	1.0	598
2	cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 1480-1485.	3.3	434
3	RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: A mechanism for diabetes-associated erectile dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 9121-9126.	3.3	297
4	Two Phases of Nitroergic Neuropathy in Streptozotocin-Induced Diabetic Rats. <i>Diabetes</i> , 2003, 52, 2353-2362.	0.3	169
5	Selective nitroergic neurodegeneration in diabetes mellitus-a nitric oxide-dependent phenomenon. <i>British Journal of Pharmacology</i> , 1999, 128, 1804-1812.	2.7	159
6	Pathophysiology of Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2005, 2, 26-39.	0.3	155
7	Physiology of Erectile Function. <i>Journal of Sexual Medicine</i> , 2004, 1, 254-265.	0.3	112
8	Y-27632, A Rho-Kinase Inhibitor, Inhibits Proliferation and Adrenergic Contraction of Prostatic Smooth Muscle Cells. <i>Journal of Urology</i> , 2003, 170, 2517-2522.	0.2	103
9	Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: A new insight into selective nitroergic neuropathy in diabetes. <i>Diabetologia</i> , 2004, 47, 331-339.	2.9	100
10	Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum. <i>British Journal of Pharmacology</i> , 2001, 133, 455-458.	2.7	94
11	Human and rabbit cavernosal smooth muscle cells express Rho-kinase. <i>International Journal of Impotence Research</i> , 2002, 14, 1-7.	1.0	85
12	Nitroergic control of peripheral sympathetic responses in the human corpus cavernosum: A comparison with other species. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 8226-8231.	3.3	79
13	The Role of Intrinsic Pathway in Apoptosis Activation and Progression in Peyronie's Disease. <i>BioMed Research International</i> , 2014, 2014, 1-10.	0.9	77
14	GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. <i>Neurogastroenterology and Motility</i> , 2009, 21, 657.	1.6	75
15	Nitroergic neurotransmission mediates the non-adrenergic non-cholinergic responses in the clitoral corpus cavernosum of the rabbit. <i>British Journal of Pharmacology</i> , 1998, 125, 1627-1629.	2.7	68
16	5-HT ₄ receptor agonists enhance both cholinergic and nitroergic activities in human isolated colon circular muscle. <i>Neurogastroenterology and Motility</i> , 2006, 18, 853-861.	1.6	63
17	Inhibition of nitroergic relaxations by a selective inhibitor of the soluble guanylate cyclase. <i>British Journal of Pharmacology</i> , 1996, 118, 137-140.	2.7	59
18	BAY41-2272, a Novel Nitric Oxide Independent Soluble Guanylate Cyclase Activator, Relaxes Human and Rabbit Corpus Cavernosum In Vitro. <i>Journal of Urology</i> , 2003, 169, 761-766.	0.2	59

#	ARTICLE	IF	CITATIONS
19	Investigation of cavernosal smooth muscle dysfunction in low flow priapism using an in vitro model. International Journal of Impotence Research, 2005, 17, 10-18.	1.0	58
20	Demonstration of Functional Neuronal β ²³ -Adrenoceptors Within the Enteric Nervous System. Gastroenterology, 2007, 133, 175-183.	0.6	56
21	Point of NO Return for Nitroergic Nerves in Diabetes: A New Insight into Diabetic Complications. Current Pharmaceutical Design, 2004, 10, 3683-3695.	0.9	55
22	The Breakdown of Preformed Advanced Glycation End Products Reverses Erectile Dysfunction in Streptozotocin-Induced Diabetic Rats: Preventive Versus Curative Treatment. Journal of Sexual Medicine, 2006, 3, 242-252.	0.3	54
23	Fatty Acylation of Phospholipase D1 on Cysteine Residues 240 and 241 Determines Localization on Intracellular Membranes. Journal of Biological Chemistry, 1999, 274, 30023-30027.	1.6	51
24	Sexual Enhancement Products for Sale Online: Raising Awareness of the Psychoactive Effects of Yohimbine, Maca, Horny Goat Weed, and <i>Ginkgo biloba</i> . BioMed Research International, 2014, 2014, 1-13.	0.9	50
25	Visualisation of nitric oxide released by nerve stimulation. , 1997, 47, 224-232.		44
26	Characterization of the non-nitroergic NANC relaxation responses in the rabbit vaginal wall. British Journal of Pharmacology, 2002, 135, 546-554.	2.7	42
27	Pathophysiology of diabetic erectile dysfunction: potential contribution of vasa nervorum and advanced glycation endproducts. International Journal of Impotence Research, 2013, 25, 1-6.	1.0	41
28	Visualisation of Nitric Oxide Generated by Activated Murine Macrophages. Biochemical and Biophysical Research Communications, 1996, 221, 37-41.	1.0	40
29	Characterization of nitroergic neurotransmission during short- and long-term electrical stimulation of the rabbit anococcygeus muscle. British Journal of Pharmacology, 1995, 115, 1149-1154.	2.7	34
30	Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. Nature Reviews Urology, 2014, 11, 231-241.	1.9	34
31	Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models. European Urology, 2019, 75, 329-340.	0.9	34
32	Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie's Disease. Sexual Medicine Reviews, 2019, 7, 679-689.	1.5	33
33	BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. Journal of Urology, 2003, 169, 761-6.	0.2	29
34	A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction. Expert Opinion on Investigational Drugs, 2002, 11, 1563-1573.	1.9	28
35	Nitroergic-noradrenergic interaction in penile erection: A new insight into erectile dysfunction. Drugs of Today, 2000, 36, 135.	0.7	28
36	Hierarchy of Membrane-targeting Signals of Phospholipase D1 Involving Lipid Modification of a Pleckstrin Homology Domain. Journal of Biological Chemistry, 2002, 277, 29152-29161.	1.6	27

#	ARTICLE	IF	CITATIONS
37	Nitrgenic Neurodegeneration in Cerebral Arteries of Streptozotocin-Induced Diabetic Rats: A New Insight into Diabetic Stroke. <i>Diabetes</i> , 2005, 54, 212-219.	0.3	24
38	Early Effect of Bariatric Surgery on Urogenital Function in Morbidly Obese Men. <i>Journal of Sexual Medicine</i> , 2017, 14, 205-214.	0.3	24
39	NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide. <i>International Journal of Impotence Research</i> , 2004, 16, 195-200.	1.0	23
40	ORIGINAL RESEARCH—BASIC SCIENCE: A Nitric Oxide-Releasing PDE5 Inhibitor Relaxes Human Corpus Cavernosum in the Absence of Endogenous Nitric Oxide. <i>Journal of Sexual Medicine</i> , 2005, 2, 53-57.	0.3	22
41	Synergy between 5-HT ₄ receptor activation and acetylcholinesterase inhibition in human colon and rat forestomach. <i>Neurogastroenterology and Motility</i> , 2008, 20, 539-545.	1.6	22
42	A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats. <i>International Journal of Impotence Research</i> , 2004, 16, 479-485.	1.0	21
43	The β -3-Adrenoceptor Agonist GW427353 (Solabegron) Decreases Excitability of Human Enteric Neurons via Release of Somatostatin. <i>Gastroenterology</i> , 2010, 138, 266-274.	0.6	21
44	Feasibility-Usability Study of a Tablet App Adapted Specifically for Persons with Cognitive Impairment—SMART4MD (Support Monitoring and Reminder Technology for Mild Dementia). <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 6816.	1.2	21
45	Potential by cholinesterase inhibitors of cholinergic activity in rat isolated stomach and colon. <i>Pharmacological Research</i> , 2008, 58, 297-301.	3.1	20
46	Understanding the Role of Adenosine Receptors in the Myofibroblast Transformation in Peyronie's Disease. <i>Journal of Sexual Medicine</i> , 2018, 15, 947-957.	0.3	18
47	Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease. <i>Journal of Sexual Medicine</i> , 2020, 17, 1848-1864.	0.3	15
48	Morphological, Chemical and Functional Analysis of Catuaba Preparations. <i>Planta Medica</i> , 2004, 70, 993-1000.	0.7	14
49	Common Pitfalls in Some of the Experimental Studies in Erectile Function and Dysfunction: A Consensus Article. <i>Journal of Sexual Medicine</i> , 2012, 9, 2770-2784.	0.3	14
50	Visualization of nitric oxide formation in cell cultures and living tissue. <i>Acta Physiologica Scandinavica</i> , 1999, 167, 161-166.	2.3	13
51	Regulation of the cardiovascular system by non-adrenergic non-cholinergic nerves. <i>Current Opinion in Nephrology and Hypertension</i> , 1997, 6, 74-79.	1.0	11
52	Nitrgenic modulation of cholinergic responses in the opossum lower oesophageal sphincter. <i>British Journal of Pharmacology</i> , 1997, 122, 1043-1046.	2.7	11
53	The Rho-kinase inhibitor Y-27632 and the soluble guanylyl cyclase activator BAY41-2272 relax rabbit vaginal wall and clitoral corpus cavernosum. <i>British Journal of Pharmacology</i> , 2003, 138, 287-290.	2.7	11
54	Functional evidence for nitrgenic neurotransmission in a human clitoral corpus cavernosum: a case study. <i>International Journal of Impotence Research</i> , 2004, 16, 319-324.	1.0	11

#	ARTICLE	IF	CITATIONS
55	Modulation of Noradrenergic Responses by Nitric Oxide from Inducible Nitric Oxide Synthase. Nitric Oxide - Biology and Chemistry, 1997, 1, 204-210.	1.2	10
56	The investigation of putative agents, using an <i>in vitro</i> model, to prevent cavernosal smooth muscle dysfunction during low-flow priapism. BJU International, 2008, 102, 988-992.	1.3	10
57	Current oral treatments for erectile dysfunction. Expert Opinion on Pharmacotherapy, 2002, 3, 1613-1629.	0.9	9
58	Let's make NO mistake!. International Journal of Impotence Research, 2005, 17, 388-389.	1.0	9
59	Challenges in sexual medicine. Nature Reviews Urology, 2012, 9, 537-542.	1.9	8
60	Single-cell Transcriptomics Uncover a Novel Role of Myeloid Cells and T-lymphocytes in the Fibrotic Microenvironment in Peyronie's Disease. European Urology Focus, 2022, 8, 814-828.	1.6	8
61	Purines and pyrimidines are not involved in NANC relaxant responses in the rabbit vaginal wall. British Journal of Pharmacology, 2002, 137, 513-521.	2.7	7
62	Cholesterol feeding attenuates endothelium-dependent relaxation response to acetylcholine in the main pulmonary artery of chickens. European Journal of Pharmacology, 1986, 129, 397-400.	1.7	6
63	Unwinding Fibrosis in Peyronie's Disease. Journal of Sexual Medicine, 2020, 17, 838-840.	0.3	5
64	Associations Between Mobile Health Technology use and Self-rated Quality of Life: A Cross-sectional Study on Older Adults with Cognitive Impairment. Gerontology and Geriatric Medicine, 2021, 7, 233372142110189.	0.8	5
65	Solving a bottleneck in animal models of peyronie's disease. Asian Journal of Andrology, 2014, 16, 639.	0.8	3
66	5-hydroxyindalpine, an agonist at the putative 5-HT1Preceptor, has no activity on human recombinant monoamine receptors but accelerates distension-induced peristalsis in mouse isolated colon. Neurogastroenterology and Motility, 2009, 21, 760-e48.	1.6	2
67	Vasa Nervorum in Rat Major Pelvic Ganglion are Innervated by Nitregric Nerve Fibers. Journal of Sexual Medicine, 2013, 10, 2967-2974.	0.3	2
68	BAY41-2272, a Novel Nitric Oxide Independent Soluble Guanylate Cyclase Activator, Relaxes Human and Rabbit Corpus Cavernosum In Vitro. Journal of Urology, 2003, , 761-766.	0.2	2
69	Histone deacetylase inhibition: a new target for peyronie's disease?. BJU International, 2014, 114, 796-796.	1.3	0
70	PS-08-017 Early effect of bariatric surgery on urogenital function in morbidly obese male patients. Journal of Sexual Medicine, 2016, 13, S116.	0.3	0
71	016 Development of a High-Throughput, Cell-Based Assay for Anti-Myofibroblast Activity in Peyronie's Disease. Journal of Sexual Medicine, 2016, 13, S8.	0.3	0
72	PS-04-004 First results from a novel cell-based assay for anti-myofibroblast activity in Peyronie's disease. Journal of Sexual Medicine, 2016, 13, S89.	0.3	0